换一批
换一批Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
作者：
主题词
成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);脱氧胞苷(Deoxycytidine);无病生存(Disease-Free Survival);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);女(雌)性(Female);氟尿嘧啶(Fluorouracil);随访研究(Follow-Up Studies);人类(Humans);输注, 静脉内(Infusions, Intravenous);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);肿瘤侵润(Neoplasm Invasiveness);肿瘤分期(Neoplasm Staging);胰腺肿瘤(Pancreatic Neoplasms);概率(Probability);喹唑啉类(Quinazolines);危险性评估(Risk Assessment);存活率分析(Survival Analysis);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1200/JCO.2008.21.5384
PMID
19858399
发布时间
2022-12-07
- 浏览2
Journal of clinical oncology
5499-505页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
